Genus Lifesciences Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENUS LIFESCIENCES, and what generic alternatives to GENUS LIFESCIENCES drugs are available?
GENUS LIFESCIENCES has seven approved drugs.
There are nineteen US patents protecting GENUS LIFESCIENCES drugs.
There are forty-four patent family members on GENUS LIFESCIENCES drugs in twenty-three countries and twenty-six supplementary protection certificates in thirteen countries.
Summary for Genus Lifesciences
International Patents: | 44 |
US Patents: | 19 |
Tradenames: | 6 |
Ingredients: | 6 |
NDAs: | 7 |
Patent Litigation for Genus Lifesciences: | See patent lawsuits for Genus Lifesciences |
Drugs and US Patents for Genus Lifesciences
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | DISCN | Yes | No | 9,539,214 | See Plans and Pricing | See Plans and Pricing | ||||
Genus Lifesciences | LEVETIRACETAM | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204754-002 | Aug 26, 2016 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-001 | Sep 14, 2016 | DISCN | Yes | No | 9,987,231 | See Plans and Pricing | See Plans and Pricing | ||||
Genus Lifesciences | YOSPRALA | aspirin; omeprazole | TABLET, DELAYED RELEASE;ORAL | 205103-002 | Sep 14, 2016 | DISCN | Yes | No | 9,539,214 | See Plans and Pricing | See Plans and Pricing | ||||
Genus Lifesciences | POTASSIUM CHLORIDE | potassium chloride | SOLUTION;ORAL | 206814-001 | Dec 22, 2014 | AA | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 81 mg/40 mg | ➤ Subscribe | 2016-10-14 |
International Patents for Genus Lifesciences Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2014007935 | See Plans and Pricing |
Japan | 2004536809 | See Plans and Pricing |
European Patent Office | 2797600 | See Plans and Pricing |
Eurasian Patent Organization | 200301321 | See Plans and Pricing |
South Africa | 201102645 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genus Lifesciences Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411900 | 18/2011 | Austria | See Plans and Pricing | PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105 |
1411900 | 132012902015795 | Italy | See Plans and Pricing | PRODUCT NAME: NAPROSSENE E ESOMEPRAZOLO SALE DI MAGNESIO TRIIDRATO(VIMOVO); AUTHORISATION NUMBER(S) AND DATE(S): PL 17901/0263-0001, 20101105;DA 40611016/M A 40611129/M, 20110808 |
1411900 | 122012000052 | Germany | See Plans and Pricing | PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
0480717 | 98C0025 | Belgium | See Plans and Pricing | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
0253310 | SPC/GB95/010 | United Kingdom | See Plans and Pricing | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.